Hudson Executive Capital Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
+$22M |
| 2 |
CIT
CIT Group Inc.
CIT
|
+$1.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CMA
Comerica
CMA
|
+$35.4M |
| 2 |
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
|
+$27.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 29.14% |
| 2 | Financials | 23.98% |
| 3 | Consumer Staples | 13.83% |
| 4 | Technology | 9.3% |
Similar funds
Hudson Executive Capital's Q2 2016 Portfolio in Review
As of Q2 2016, Hudson Executive Capital held 13 positions worth $267M, down 39% from $434M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Hudson Executive Capital withdrew a net $179M in Q2 2016, closing 4 positions and reducing 3 holdings. Its most notable exit was HEARTWARE INTERNATIONAL INC COM STK (DE), an estimated $27.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 29% of assets, up from 14% a quarter earlier, followed by Financials and Consumer Staples.
Against the trend, Hudson Executive Capital added an estimated $22M to Eagle Pharmaceuticals, Inc..
- Hudson Executive Capital added most to Eagle Pharmaceuticals, Inc. in Q2 2016, an estimated $22M increase.
- Hudson Executive Capital's biggest Q2 2016 reduction was Comerica, cutting an estimated $35.4M.
- Hudson Executive Capital fully exited HEARTWARE INTERNATIONAL INC COM STK (DE) in Q2 2016, selling an estimated $27.2M.
- Hudson Executive Capital's ten largest holdings make up 100% of its $267M portfolio in Q2 2016.
- Hudson Executive Capital opened 1 new position and closed 4 in Q2 2016.
- Hudson Executive Capital's portfolio value fell 39% quarter-over-quarter to $267M.
Based on Hudson Executive Capital's 13F filing for Q2 2016, filed 15 Aug 2016.